The Efficacy of an Ocular Emulsion in Meibomian Gland Dysfunction

Completed · Not applicable

Conditions studied: Meibomian Gland Dysfunction

In brief

The aim of this study will be to determine the efficacy of this novel, lipid-containing artificial tear on the signs and symptoms of meibomian gland disease.

Key facts

Study ID

NCT01207752

Run by

Southern California College of Optometry at Marshall B. Ketchum University

People needed

69

Starts

2010-09-01

Expected to finish

2011-07-01

Last updated by the study team

2025-04-01

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Schein symptom score (all 6 questions) of greater than 5,
• evidence of MGD changes in both eyes (i.e.,
• lower eyelid secretion quality score greater than 1.0 (0 - 3 scale) OR gland dropout score greater than 1.0 (i.e., greater than 25% of entire lower eyelid) as demonstrated by meiboscopy, and corneal staining of grade 4.0 or greater (0 - 20 scale).

You may not qualify if…

• contact lens wear, use of topical ocular medication other than artificial tears (use of Restasis is specifically excluded),
• unstable systemic medication use (i.e., anti-histamines, steroids, etc.), recent (within 6 months of study start) ocular trauma or surgery,
• diabetes, aqueous deficient dry eye (defined as a Schirmer I value (without anesthetic) of < 5 mm of wetting in 5 minutes in either eye), and use of punctal plugs.
• Subjects taking omega 3 fatty acid supplements for dry eye can be included so long as their intake is stable for the prior six months and they meet the inclusion criteria above. -

Where it is running

• Eye Care Center — Fullerton, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.